Summary The role of two common polymorphisms of enzymes involved in the metabolism of drugs and carcinogens was studied in relation to prostate cancer. The gene encoding one of these enzymes (NAT2) is located in an area where frequent allelic loss occurs in prostate cancer. Mutations at the genes CYP2D6 and NAT2 were analysed by allele-specific polymerase chain reaction and restriction mapping in DNA from 94 subjects with prostate cancer and 160 male healthy control subjects. Eleven prostate specimens were analysed for genotype and enzymatic activities NAT2, CYP2D6 and CYP3A by using the enzyme-specific substrates sulphamethazine and dextromethorphan. Enzyme activities with substrate specificities corresponding to NAT2, CYP2D6 and CYP3A are present in human prostate tissue, with mean ± s.d. activities of 4.8 ± 4.4 pmol min-' mg-' protein, 156 ± 91 and 112 ± 72 nmol min-' mg-' protein respectively. The Km, values for the prostate CYP2D6 and CYP3A enzyme activities corresponded to that of liver CYP2D6 and CYP3A activities, and the CYP2D6 enzyme activity is related to the CYP2D6 genotype. The N-acetyftransferase, in contrast, had a higher Km than NAT2 and was independent of the NAT2 genotype. The CYP2D6 and CYP3A enzymes, and an N-acetyttransferase activity that is independent of the regulation of the NAT2 gene. are expressed in human prostate tissue. The presence of carcinogen-metabolizing enzymes in human prostate with a high interindividual variability may be involved in the regulation of local levels of carcinogens and mutagens and may underie interindividual differences in cancer susceptibility. 1362 JAG Agundez et al due to a strong local effect on the actixation or deactivation of carcinogens in situ. For instance. it has been shovA-n that N-acetvltransferase polx morphism play s a relevant role in the formation of 2-aminofluorene-DNA adducts in tumour target organs (Feng et al. 1996). In an attempt to elucidate the events that occur as previous steps to prostate carcinogenesis. x e hax e studied A hether the poix-morphic enzymes CYP2D6 and NAT2 are actix ely expressed in human prostate tissue. as well as the impact of such genetic polx morphisms in prostate cancer susceptibility. In order to ex aluate w-hether allelic loss of these genes occurs in adenomatous prostate tissue. the occurrence of allelic losses at the CYP2D and .VA72 gene loci in prostate tissues was also studied. If the CYP2D6 enzyrme is functionally expressed in prostate. allelic loss of CYP2D6 could cause changes in local enzyme activity. modifving the local metabolism of carcinooens and mutarens. To our know-ledge. no studies involving allelic loss of the polymorphic gene CYP2D6 haxe been performed. This is also the first study inxolxing allelic loss of the NVA72 gene in prostate. Indeed only one study involvin2 allelic loss of NAT2 has been published. and it was performed in colon cancer (Hubbard et al. 1997 ).
prostate cancer risk. The polymorphisms studied have been proposed as cenetic biomarkers for susceptibilitV to some forms of cancer. It should be pointed out that the role of such poly morphisms on cancer risk should be considered as preliminary and controversial. Howexer. the polymorphic CYP2D6 gene seems to be inxolved in susceptibilitx to luna and liver cancer (AgIndez et al. 1995a : Bouchardx et al. 1996 . .VA72 is a gene of likelv importance in bladder and liver carcinogenesis. as subjects w-ith enzn-meinactivatinc mutations are at increased risk of dexelopinc bladder and lixer cancer (Caporaso et al. 1991 : Agtindez et al. 1996a ). The g-ene coding, for the NAT2 enzx-me is located in the short arm of chromosome 8. in the same area in w-hich the most frequent allelic loss occurs in prostate cancer tissue (Bergyenheim et al. 1991 : Franke et al. 1994 : Vatsis et al. 1995 . The loss of a aene codine for an enzN-me involved in the detoxification of carcinogens or mutag,ens could constitute a risk factor for carcinocenesis.
To date. no studies involxing a possible association of prostate cancer and the polymorphisms studied here haxe been published.
Another point that has not been elucidated is w hether the CYP2D6 and NAT2 enzymes are functionally expressed in human prostate tissue. Expression of an N-acetxyltransferase actixity in rat and doc prostate has been shown (Hein et al. 1991 : Sone et al. 1994 . but the identitx of such an enzyme remains unclear. Recent studies also indicate the presence of cytochrome P450 enzy mes in human prostate cancer tissues (Murrav et al. 1995) . So far. most associations betw een polymorphic drug metabolizing enzymes and carcinogenesis haxe been demonstrated in tissues in which the enzymes are expressed (Caporaso et al. 1991) . This is probably 1361 due to a strong local effect on the actixation or deactivation of carcinogens in situ. For instance. it has been shovA-n that N-acetvltransferase polx morphism play s a relevant role in the formation of 2-aminofluorene-DNA adducts in tumour target organs (Feng et al. 1996) . In an attempt to elucidate the events that occur as previous steps to prostate carcinogenesis. x e hax e studied A hether the poix-morphic enzymes CYP2D6 and NAT2 are actix ely expressed in human prostate tissue. as well as the impact of such genetic polx morphisms in prostate cancer susceptibility. In order to ex aluate w-hether allelic loss of these genes occurs in adenomatous prostate tissue. the occurrence of allelic losses at the CYP2D and .VA72 gene loci in prostate tissues was also studied. If the CYP2D6 enzyrme is functionally expressed in prostate. allelic loss of CYP2D6 could cause changes in local enzyme activity. modifving the local metabolism of carcinooens and mutarens. To our know-ledge. no studies involving allelic loss of the polymorphic gene CYP2D6 haxe been performed. This is also the first study inxolxing allelic loss of the NVA72 gene in prostate. Indeed only one study involvin2 allelic loss of NAT2 has been published. and it was performed in colon cancer (Hubbard et al. 1997 ).
METHODS

Patients and controls
All the subjects included in this studx were unrelated v hite Spanish men. samples from the same patients w-ere obtained for comparison and for the study of aenetic changes in the prostate tissue. Human liver samples were used for comparison with the enzyme activities identified in prostate tissue. These samples were biopsies obtained from patients undergoinc surgery. as described elsewhere (Agindez et al. 1990 ). The cytosolic and microsomal fractions from prostate and liver tissues were performed as described elsewhere (Agdndez et al. 1990 : Grant et al. 1990 ).
Enzymatic assays
The analy ses of enzy matic activities w ere carried out bx the use of substrates specific for the NAT2 and the CYP2D6 enzymes. Nacetyltransferase activity was anal sed by using sulphamethazine as described elsewhere (Grant et al. 1990 ). The amount of parent drug and the acetylated metabolite A ere determined bx highperformance liquid chromatographv (HPLC) analysis (Grant et al. 1990 ). The CYP2D6 activity was analysed by the use of NAT2 and CYP2D6 polymorphisms in prostate cancer 1363
NADPH. 50 mms glucose-6-phosphate and four enzxme units of glucose-6-phosphate dehydrogenase). 5 mM\ magnesium chloride.
50 \iM dextromethorphan and 50-100 jg> of microsomal protein in 10 mnm Tris-HCl buffer. pH 7.5. in a final volume of 250 gl. The reaction was started with the addition of microsomes and ,A-as carried out at 37-C for 30 min. then stopped by the addition of 20 gl of 15% perchloric acid. The mixture was frozen for 30 min. and centrifuged at 12 000 x g for 10 min. An aliquot of 20 gl of the supernatant w-as analysed for parent drug and metabolites by HPLC analysis and fluorescence detection (Chen et al. 1990 (. Besides the CYP2D6 actixity. as calculated from the rate of production of dextrorphan. the analvsis of the dextromethorphan metabolite 3-methoximorphinan permits the determination of the CYP3A activitx (Kerrv et al. 1994) . Therefore. the measurements of CYP3A actixitx in every prostate specimen w-ere carried out under identical conditions to those of CYP2D6 activity except that the concentration of dextromethorphan x-as 4 mi\. For the Km analvsis of the CYP3A actixity. dextrorphan instead of dextromethorphan was used (Kerrx et al. 1994) . All the measurements wxere performed at least in triplicate and in incubation time and enzyme quantity linear conditions.
DNA isolation and analyses
Genomic DNA was purified from peripheral leucocytes and from prostate tissues using standard protocols (Neitzel. 1986 ) and kept in sterile plastic vials at 4'C until analx sis. The NAT2 polymorphism was studied bx the use of a PCRbased analysis. Which was carried out in txxo steps. First. a fragment containing the coding region and a part of the 5' and 3' flankinc regions of the NA4T2 ene was amplified (Agtindez et al. 1994 ). The 1213-bp product was used as a template for a set of seven pairs of secondar-mutation-specific PCR reactions (one for everv mutation studied). The association of several mutations in the same allele w-as studied by mutation-specific PCR andlor restriction mapping of the PCR products. The mutations studied were: 191A. 282T. 341C. 481T. 590A. 803G and 857A. All these mutations are within the coding rerion of the NAT2 gene. These mutations. isolated or combined. have been reported as being present in several allelic variants. all of which w-ere identifiable by the methods used in this study (Agtndez et al. 1996b ). Details about the method used are described elsewhere (Martinez et al. 1995) . The CYP2D6 genotyping w as carried out by the combined use of mutation-specific PCR and restriction mapping with the enzymes EcoRI and XbaI as described elsewhere (Skoda et al. 1988 : Gaediak et al. 1991 : Tvndale et al. 1991 : Heim and Meyer. 1991 : Johansson et al. 1993 . The analyses performed permitted the identification of the allelic variants CYP2D6*1 )wild type). two active allelic variants (CYP2D6*2 and CYP2D6*9). txo defective allelic -ariants (CYP2D6*3 and CYP2D6*4) and the occurrence of complete gene deletion (CYP2D6*5) as well as gene duplications or amplifications (CYP2D6*x2 and CYP2D6*>n).
Sequence analysis of the NAT1 gene in prostate specimens A fragment spanning the whole coding recion of the human MATi gene. as vvell as 5' and 3' flanking regions. w-as amplified and sequenced as follows. Genomic DNA obtained from all prostate specimens w-as subject to a PCR amplification by using the The results are mean -s.d. of at least three independent measurements. In the evaluation of the results no subgroups were made as no genetic polymorphisms of the CYP3A activity has been shown. The results are summarized in the text. Twenty different NAT2 genotypes were identified in this study. Only those present in 20% of subjects or over, either among cases or control subjects. are listed in the table. The rest of the genotypes are induded in the group of rare genotypes at the end of the table. The intergroup comparison analyses indicate that no statistcally significant differences exist between cases and control subjects. In all cases P-value was > 0.05. The relative risk ratio for slow acetylators is 1.1 (950 Cl = 0.7-1.9).
primers TCAAATCCAAGTGTAAAAGT (position -62 to -43) and GATACATGATAGGTCGTC [position 946 to 929 of the NATI gene according to Blum et al (1990) ]. PCR amplification was carried out for 35 cycles of 1 min at 94-C. I min at 45-C and I min at 72zC and a final extension period of 7 min at 72'C. The amplified fragrment contains the mutations present in most allelic
x-ariants of the VATI gene. includinc the allelic -ariants N\ATJ *5.
4 ATI *11. NAT1*14. NIATI*15 and NATI*17. The allelic X ariant NATi *4 (w ild tvpe) is defined by the absence of mutations (for a rexiexx. see Grant et al. 1997 For CYP2D. the samples w-ere studied after digestion wxith the enz\ me EcoRl. and the Southern blot analv-sis wxas carried out as described elsew-here b\-using as a probe the CYP2D6 cDN-A that \vas kindly prox-ided by Professor tUrs A Meyer (Basle. Sxx itzerland ). Details of the method are described elsewxhere (Johansson et al. 1993 I.
For the analysis ofY4AT2. a 931 -bp PCR-amplified DNA frayment obtained in the second amplification reaction of the .\AT2 aenotvping, (Martinez et al. 1995) x-as purified b\-agarose gel electrophoresis. reamplified under identical PCR conditions and used as a probe. The occurrence of mutations at position 590 of the gene causes loss of the laqI restriction site: therefore. the nonmutated genes gixve digestion products of 664 and 267 bp. x-hereas the mutated genes gixve a sinole band of 931 bp.
The probes for both genes analysed xxere labelled by random priming xxith digoxigenin-ll-dUTP. using a digoxigenin DNA labelling! and detection kit X Boehringer Mannheim. Barcelona (Gonzalez et al. 1988 ). The difference observed xxas not statisticallx significant because of the small sample size.
The method used for the determination of CYP2D6 actixvitv also permits the determination of the CYP3A actixitx. xxhich carries out the N-demethvlation of dextromethorphan (Kerrx et al. 1994 As no genetic polymorphism for CYP3A actixvity has been described. all the samples xxere considered to belong to the same group (Table  3) . The mean ± s.e. actixitx is 112 ± 72 nmol mmn-mg-protein (range 39-278 ) . This represents an enzy me actixvity about ten times lowxer than that measured in human lixer microsomes (Kerrv et al. 1994 P11 and P12. were analy-sed for CYP2D6 allelic loss. Seven samples with heterozygosity at the A.AT2 gene w-ere analy sed for allelic loss. These were P02. P03. P04. P05. P08 and P12. For this. Southern blotting of the DNA samples digested wxith adequate restriction enzy-mes (see Methods) x was performed and the completion of the digestion x as ex aluated by comparing the band densities obtained in the DNA samples from blood and prostate. which xwere digested and electrophoresed in parallel. After obtaining semiquantitative Southern blot conditions. the band densities w-ere compared in blood and prostate DNA. The complementaranalvsis of the leucocv-te DNA rules out the possibility that subjects with a complete allelic loss in prostate tissue w-ould be misclassified as homoz-gous for the remainin2 allele. In such a case. a discrepancy betx-een prostate and leucocyte DNA w-ould be apparent. No such discrepancies A-ere observed. and no allelic losses could be evidenced in any adenomatous prostate sample. Figure 1 shows typical analyses of allelic loss at CYP2D6 and .M4T2 renes. (Vineis et al. 1994 ). Recently we also described an association of low NAT2 activity with primar-liver cancer (Agundez et al. 1996a> .
It should be pointed out that the enzyme poly-morphisms analysed in the present study seem to be involved in carcinogenesis through the modulation of the levels of active carcinogens and mutagens. although with apparently inverse effect. C-tochrome P450 enzymes are usuallv involved in the activation of environmental and food carcinogens. These include nitrosamines. aflatoxin B 1. as well as polycyclic aromatic hydrocarbons and heterocy-clic amines (Aoyama et al. 1990 : Crespi et al. 1991 : Degawa et al. 1994 : Yanagawa et al. 1994 . Accordingly. subjects with high CYP2D6 enzyme activity are at increased risk of developinc lung and liver cancer (Aguindez et al. 1995a : Bouchardv et al. 1996 . In contrast. NAT2 enzyme acts as a detoxifying system for arvlamines and hvdrazines throurh N-acetvlation (Hein. 1988 : Guengerich. 1991 : Hein et al. 1993 ). In fact. epidemiological studies showed that the subjects with low NAT2 activity are at increased risk of developing cancer of the bladder and larynx (for a review, see Evans. 1992 ). In addition. the joint effects of NtAT] and N.AT2 should be considered. as this 2ene-aene effect has been reported for bladder carcinogenesis (Kloth et al. 1994 : Badawi et al. 1995 : Kadlubar and Badawi. 1995 . Our findings in prostate specimens do not indicate anv association of N-acetvltransferase activit-with the NAT] or the VAAT genotypes. or a joint effect caused bv both of them.
Our findings indicate a lack of relationship between the A7M42 genotype and prostate cancer risk. This. together with the lack of association between the N-acet-lation activitv and the .\AA genotVpe in prostate tissue. virtually rules out anv major association bet,ween the polvmorphism of the NAT2 enzyme and prostate cancer risk. Our findings also indicate that. despite the presence of CYP2D6. CYP3A and N-acetylation enzyme activities in prostate. the poly-morphisms of the CYP2D6 and NAT2 enzymes are not linked to a particular susceptibility to develop prostate cancer.
However. carcinogen-specificity analyses of the enzyme activities present in human prostate tissue will be required to provide definitive answers to whether these enzymes are involved in processes of activation or deactivation of carcinogens and mutagens. thereby beinc innvolved in the aetiology of prostate cancer.
